MDGL · Madrigal Pharmaceuticals Inc
United States · RS rating 25 · As of 2026-11-03
| Price | 396.32 USD |
|---|---|
| 1-day change | -8.1% |
| RS rating (overall / 1M / 3M / 12M) | 25 / 22 / 28 / 46 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 32 / 6 / 47 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +49.4% |
| Sales growth Q/Q | +11.8% |
| Distance from 52-week high | +34.3% |
| Market cap (USD) | $11.9B |